




RealRate

PHARMACEUTICAL 2023

Salarius Pharmaceuticals Inc. Rank 377 of 446





RealRate

PHARMACEUTICAL 2023

Salarius Pharmaceuticals Inc. Rank 377 of 446



The relative strengths and weaknesses of Salarius Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Salarius Pharmaceuticals Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 24% points. The greatest weakness of Salarius Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 213% points.

The company's Economic Capital Ratio, given in the ranking table, is -145%, being 188% points below the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	14,520
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,858
Liabilities, Non-Current	0
Other Assets	131
Other Compr. Net Income	0
Other Expenses	8,851
Other Liabilities	1,408
Other Net Income	219
Other Revenues	0
Property and Equipment	0
Research and Development	15,837
Selling, General and Administrative Expense	7,138

Output Variable	Value in 1000 USD
Assets	14,651
Liabilities	4,266
Expenses	31,827
Revenues	0
Stockholders Equity	10,385
Net Income	-31,608
Comprehensive Net Income	-31,608
Economic Capital Ratio	-145%